Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-731-8180
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees117
Next Earnings Date5/2/2019 (Estimated)
OptionableNot Optionable
Odonate Therapeutics (NASDAQ:ODT) Frequently Asked Questions
What is Odonate Therapeutics' stock symbol?
Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."
How were Odonate Therapeutics' earnings last quarter?
Odonate Therapeutics Inc (NASDAQ:ODT) posted its quarterly earnings data on Friday, February, 22nd. The company reported ($1.17) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.07) by $0.10. View Odonate Therapeutics' Earnings History.
When is Odonate Therapeutics' next earnings date?
What is the consensus analysts' recommendation for Odonate Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Odonate Therapeutics.
What are Wall Street analysts saying about Odonate Therapeutics stock?
Here are some recent quotes from research analysts about Odonate Therapeutics stock:
- 1. According to Zacks Investment Research, "Odonate Therapeutics, LLC is a pharmaceutical company. It engaged in the development of therapeutics to improve and extend the lives of patients with cancer. The company focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer. Odonate Therapeutics, LLC is based in SAN DIEGO, United States. " (3/2/2019)
- 2. Cowen Inc analysts commented, "We believe current valuation is a compelling entry point for investors and we expect the stock should begin to work in anticipation of these results with shares reaching ~$40, if data are positive." (2/22/2019)
Has Odonate Therapeutics been receiving favorable news coverage?
Media stories about ODT stock have trended positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Odonate Therapeutics earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future.
Who are some of Odonate Therapeutics' key competitors?
Some companies that are related to Odonate Therapeutics include Portola Pharmaceuticals (PTLA), Mirati Therapeutics (MRTX), Arena Pharmaceuticals (ARNA), PTC Therapeutics (PTCT), The Medicines (MDCO), Uniqure (QURE), AnaptysBio (ANAB), Endocyte (ECYT), Myokardia (MYOK), Nabriva Therapeutics (NBRV), Supernus Pharmaceuticals (SUPN), Heron Therapeutics (HRTX), Xencor (XNCR), Ironwood Pharmaceuticals (IRWD) and Arrowhead Pharmaceuticals (ARWR).
What other stocks do shareholders of Odonate Therapeutics own?
Who are Odonate Therapeutics' key executives?
Odonate Therapeutics' management team includes the folowing people:
- Mr. Kevin C. Tang, Chairman & CEO (Age 52)
- Mr. John G. Lemkey, Chief Operating Officer (Age 38)
- Dr. Joseph P. O'Connell M.D., Chief Medical Officer (Age 65)
- Mr. Michael S. Hearne, CFO & Principal Accounting Officer (Age 57)
- Dr. Steven S. Pfeiffer Ph.D., VP of Technical Operations (Age 43)
When did Odonate Therapeutics IPO?
(ODT) raised $150 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 5,900,000 shares at a price of $24.00-$27.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Cowen was co-manager.
How do I buy shares of Odonate Therapeutics?
Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Odonate Therapeutics' stock price today?
One share of ODT stock can currently be purchased for approximately $21.40.
How big of a company is Odonate Therapeutics?
Odonate Therapeutics has a market capitalization of $572.51 million. The company earns $-88,960,000.00 in net income (profit) each year or ($3.64) on an earnings per share basis. Odonate Therapeutics employs 117 workers across the globe.
What is Odonate Therapeutics' official website?
How can I contact Odonate Therapeutics?
Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]
MarketBeat Community Rating for Odonate Therapeutics (NASDAQ ODT)
MarketBeat's community ratings are surveys of what our community members think about Odonate Therapeutics and other stocks. Vote "Outperform" if you believe ODT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ODT will underperform the S&P 500 over the long term. You may vote once every thirty days.
